Sign in
Enrolling by invitationPhase 2

Inhaled Nitric Oxide for Microvascular Dysfunction in Traumatic Brain Injury

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Status
Enrolling by invitation
Phase
Phase 2
People taking part
38 people, planned
Started
6 Apr 2025
Expected to end
28 Mar 2028
Type of study
Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • inhaled nitric oxide
Record updated
17 June 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Aged 18-75 (inclusive)
  • GCS 9-12 or GCS 13-15 with an abnormal imaging scan
  • Radiologic findings indicative of primarily diffuse TBI

Who cannot take part

  • Severe cardiac dysfunction (e.g. elevation of pulmonary edema on chest xray, large elevation of cardiac enzymes)
  • Pre-existing disabling psychiatric or neurological disorders such as cortical stroke, brain tumor, disabling multiple sclerosis, dementia, and severe TBI
  • Known intracranial vessel disease
  • Acute Respiratory Distress Syndrome (ARDS) or pre-existing pulmonary hypertension
  • Chronic Kidney Disease (Glomerular Filtration Rate <60mL/min/1.73m2)
  • Respiratory Infection
  • Possible drug interactions (nitric oxide donors: prilocaine, sodium nitroprusside, nitroglycerin)
  • Large focal injury (subdural hematoma, epidural hematoma, intraparenchymal hematoma, >30mL aggregate volume)
  • Need for immediate neurosurgical intervention
  • Cardiopulmonary resuscitation or cardioversion at admission
  • Prisoners, patients in police custody, pregnant women

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

  • Penn Presbyterian Medical CenterPhiladelphia, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Traumatic brain injury (TBI) causes acute deficits in cerebral perfusion which may lead to secondary injury and worse outcomes. Inhaled nitric oxide (iNO) is a vasodilator that increases cerebral blood flow and is clinically used for hypoxic respiratory failure in neonates and adults. The investigators will perform a randomized controlled trial of iNO treatment in TBI patients acutely after injury. The investigators will then assess perfusion changes with optic neuromonitoring, blood biomarkers, and 6 month clinical outcomes.

The 2 groups in the trial

  • Group iNOTreatment being tested

    Subjects will receive iNO for 4 hours, followed by standard respiratory support (SRS) for 4 hours. This pattern will be reversed the next day (SRS then iNO). on the following day, the pattern will be reversed back to iNO for 4 hours and SRS for 4 hrs.

    Treatment: inhaled nitric oxide

  • Group SRSSham treatment, for comparison

    Subjects will receive standard respiratory support (SRS) for 8 hours.

    Treatment: inhaled nitric oxide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT05616910, who can take part
Record updated
17 June 2026